These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1202 related items for PubMed ID: 22613095

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, Bhalla KN.
    Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
    [Abstract] [Full Text] [Related]

  • 4. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S.
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC, Chen S.
    Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines.
    De Santi M, Galluzzi L, Lucarini S, Paoletti MF, Fraternale A, Duranti A, De Marco C, Fanelli M, Zaffaroni N, Brandi G, Magnani M.
    Breast Cancer Res; 2011 Mar 24; 13(2):R33. PubMed ID: 21435243
    [Abstract] [Full Text] [Related]

  • 11. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW, Yeh YL, Wang YC, Huang WJ, Ho SY, Lin P, Wang YJ.
    Mol Cancer; 2016 Jun 10; 15(1):46. PubMed ID: 27286975
    [Abstract] [Full Text] [Related]

  • 12. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW, Huang CY, Tam KW, Lin CY, Huang LC, Lin CL, Hsieh WS, Chi WM, Chang YJ, Wei PL, Chen ST, Lee CH.
    Int J Mol Sci; 2018 Feb 02; 19(2):. PubMed ID: 29393914
    [Abstract] [Full Text] [Related]

  • 13. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A.
    Melanoma Res; 2013 Oct 02; 23(5):341-8. PubMed ID: 23963286
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
    Lin Z, Zhang Z, Jiang X, Kou X, Bao Y, Liu H, Sun F, Ling S, Qin N, Jiang L, Yang Y.
    Oncotarget; 2017 Mar 14; 8(11):17833-17848. PubMed ID: 28147319
    [Abstract] [Full Text] [Related]

  • 16. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ.
    PLoS One; 2013 Mar 14; 8(10):e76340. PubMed ID: 24130769
    [Abstract] [Full Text] [Related]

  • 17. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
    Lin YS, Chiu YC, Tsai YH, Tsai YF, Wang JY, Tseng LM, Chiu JH.
    J Cell Biochem; 2019 Aug 14; 120(8):13531-13544. PubMed ID: 30957305
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.
    Hahne JC, Schmidt H, Meyer SR, Engel JB, Dietl J, Honig A.
    J Cancer Res Clin Oncol; 2013 Jun 14; 139(6):905-14. PubMed ID: 23440492
    [Abstract] [Full Text] [Related]

  • 19. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
    LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD.
    Cancer Res; 2011 May 15; 71(10):3635-48. PubMed ID: 21464044
    [Abstract] [Full Text] [Related]

  • 20. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Hugo HJ, Gunasinghe NPAD, Hollier BG, Tanaka T, Blick T, Toh A, Hill P, Gilles C, Waltham M, Thompson EW.
    Breast Cancer Res; 2017 Jul 27; 19(1):86. PubMed ID: 28750639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.